{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:10:37Z","timestamp":1715904637969},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2013,8,5]],"date-time":"2013-08-05T00:00:00Z","timestamp":1375660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0070952","type":"journal-article","created":{"date-parts":[[2013,8,5]],"date-time":"2013-08-05T21:22:15Z","timestamp":1375737735000},"page":"e70952","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neuronal Apoptosis and Motor Deficits in Mice with Genetic Inhibition of GSK-3 Are Fas-Dependent"],"prefix":"10.1371","volume":"8","author":[{"given":"Raquel","family":"G\u00f3mez-Sintes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 J.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,8,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1242\/jcs.00384","article-title":"GSK-3: tricks of the trade for a multi-tasking kinase","volume":"116","author":"BW Doble","year":"2003","journal-title":"J Cell Sci"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3590001","article-title":"GSK3 takes centre stage more than 20 years after its discovery","volume":"359","author":"S Frame","year":"2001","journal-title":"Biochem J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0301-0082(01)00011-9","article-title":"The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling","volume":"65","author":"CA Grimes","year":"2001","journal-title":"Prog Neurobiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrn2870","article-title":"GSK3 signalling in neural development","volume":"11","author":"EM Hur","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tibs.2003.12.004","article-title":"The glamour and gloom of glycogen synthase kinase-3","volume":"29","author":"RS Jope","year":"2004","journal-title":"Trends Biochem Sci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1460-9568.2006.05245.x","article-title":"Glycogen synthase kinase-3 inhibition is integral to long-term potentiation","volume":"25","author":"C Hooper","year":"2007","journal-title":"Eur J Neurosci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2007.01.029","article-title":"LTP inhibits LTD in the hippocampus via regulation of GSK3beta","volume":"53","author":"S Peineau","year":"2007","journal-title":"Neuron"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2174\/1389450110607011399","article-title":"Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders","volume":"7","author":"TD Gould","year":"2006","journal-title":"Curr Drug Targets"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2174\/1389450110607011421","article-title":"Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions","volume":"7","author":"RS Jope","year":"2006","journal-title":"Curr Drug Targets"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.tins.2008.07.007","article-title":"Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'?","volume":"31","author":"T Kato","year":"2008","journal-title":"Trends Neurosci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng1296","article-title":"Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia","volume":"36","author":"ES Emamian","year":"2004","journal-title":"Nat Genet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer's disease","volume":"104","author":"C Hooper","year":"2008","journal-title":"J Neurochem"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnmol.2011.00017","article-title":"GSK3 and Alzheimer's Disease: Facts and Fiction","volume":"4","author":"A Kremer","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"33791","DOI":"10.1074\/jbc.M204861200","article-title":"Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation","volume":"277","author":"J Carmichael","year":"2002","journal-title":"J Biol Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/npp.2011.128","article-title":"Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease","volume":"36","author":"CT Chiu","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/cdd.2009.127","article-title":"PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K\/Akt pro-survival pathway in Huntington's disease striatum","volume":"17","author":"A Saavedra","year":"2010","journal-title":"Cell Death Differ"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2174\/1389450110607011435","article-title":"Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes","volume":"7","author":"EJ Henriksen","year":"2006","journal-title":"Curr Drug Targets"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0065-230X(02)84007-6","article-title":"Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways","volume":"84","author":"AS Manoukian","year":"2002","journal-title":"Adv Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrd1415","article-title":"GSK3 inhibitors: development and therapeutic potential","volume":"3","author":"P Cohen","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tips.2004.07.006","article-title":"Pharmacological inhibitors of glycogen synthase kinase 3","volume":"25","author":"L Meijer","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1017\/S1461145704004535","article-title":"AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test","volume":"7","author":"TD Gould","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0960-9822(02)70790-2","article-title":"Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells","volume":"6","author":"V Stambolic","year":"1996","journal-title":"Curr Biol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.93.16.8455","article-title":"A molecular mechanism for the effect of lithium on development","volume":"93","author":"PS Klein","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1172\/JCI37873","article-title":"NFAT\/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy","volume":"120","author":"R Gomez-Sintes","year":"2010","journal-title":"J Clin Invest"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Macritchie KAN, Young AH (2004) Adverse syndromes associated with lithium. In: Haddad P, Dursun S, Deakin B, editors. Adverse Syndromes and Psychiatric Drugs: A Clinical Guide: Oxford University Press. 89\u2013109.","DOI":"10.1093\/med\/9780198527480.003.0006"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35017574","article-title":"Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation","volume":"406","author":"KP Hoeflich","year":"2000","journal-title":"Nature"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/sj.emboj.7601725","article-title":"Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice","volume":"26","author":"R Gomez-Sintes","year":"2007","journal-title":"Embo J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pneurobio.2006.07.006","article-title":"The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways","volume":"79","author":"E Beurel","year":"2006","journal-title":"Prog Neurobiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"9494","DOI":"10.1073\/pnas.86.23.9494","article-title":"Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo","volume":"86","author":"R Beyaert","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2202-5-20","article-title":"Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor","volume":"5","author":"L Song","year":"2004","journal-title":"BMC Neurosci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1146\/annurev.pharmtox.41.1.789","article-title":"Molecular targets of lithium action","volume":"41","author":"CJ Phiel","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref32","unstructured":"Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates: Academic Press."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.physbeh.2004.04.006","article-title":"Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome","volume":"82","author":"TG Hampton","year":"2004","journal-title":"Physiol Behav"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-0270(96)02211-X","article-title":"Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion","volume":"73","author":"K Matsuura","year":"1997","journal-title":"J Neurosci Methods"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.iy.09.040191.001331","article-title":"Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease","volume":"9","author":"PL Cohen","year":"1991","journal-title":"Annu Rev Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0192-0561(94)90021-3","article-title":"Long-term treatment with 5,5-diphenylhydantoin reduces lymphadenopathy and anti-ssDNA autoantibodies in C57BL\/6-lpr\/lpr mice","volume":"16","author":"N Bloksma","year":"1994","journal-title":"Int J Immunopharmacol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2165\/00023210-200216110-00001","article-title":"Treatment research in bipolar disorder: issues and recommendations","volume":"16","author":"RJ Baldessarini","year":"2002","journal-title":"CNS Drugs"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1359786806063072","article-title":"Lithium in maintenance therapy for bipolar disorder","volume":"20","author":"AH Young","year":"2006","journal-title":"J Psychopharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial","volume":"198","author":"OV Forlenza","year":"2011","journal-title":"Br J Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/gps.1964","article-title":"A feasibility and tolerability study of lithium in Alzheimer's disease","volume":"23","author":"A Macdonald","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref41","first-page":"533","article-title":"Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic","volume":"11","author":"M Medina","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2008.10.007","article-title":"GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals","volume":"33","author":"S Hu","year":"2009","journal-title":"Neurobiol Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0960-9822(02)01140-5","article-title":"Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity","volume":"12","author":"DW Ethell","year":"2002","journal-title":"Current biology : CB"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0006-8993(00)02363-5","article-title":"Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations","volume":"869","author":"M Martinez","year":"2000","journal-title":"Brain research"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0969-9961(02)00019-0","article-title":"Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death","volume":"12","author":"JH Su","year":"2003","journal-title":"Neurobiology of disease"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1126\/science.290.5500.2302","article-title":"Evidence for genetic linkage of Alzheimer's disease to chromosome 10q","volume":"290","author":"L Bertram","year":"2000","journal-title":"Science"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1126\/science.290.5500.2304","article-title":"Susceptibility locus for Alzheimer's disease on chromosome 10","volume":"290","author":"A Myers","year":"2000","journal-title":"Science"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s004390000383","article-title":"apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene","volume":"107","author":"L Feuk","year":"2000","journal-title":"Human genetics"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jalz.2009.05.663","article-title":"The FAS gene, brain volume, and disease progression in Alzheimer's disease","volume":"6","author":"D Erten-Lyons","year":"2010","journal-title":"Alzheimer's & dementia : the journal of the Alzheimer's Association"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/cdd.2008.124","article-title":"Identification of an antiapoptotic protein complex at death receptors","volume":"15","author":"M Sun","year":"2008","journal-title":"Cell Death Differ"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jnr.22253","article-title":"Fas activation increases neural progenitor cell survival","volume":"88","author":"JC Knight","year":"2010","journal-title":"J Neurosci Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1523\/JNEUROSCI.3183-05.2005","article-title":"Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease","volume":"25","author":"M Diaz-Hernandez","year":"2005","journal-title":"J Neurosci"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.bcp.2008.07.034","article-title":"Non-apoptotic functions of caspase-8","volume":"76","author":"J Maelfait","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.tins.2008.06.007","article-title":"Death receptor Fas (CD95) signaling in the central nervous system: tuning neuroplasticity?","volume":"31","author":"A Reich","year":"2008","journal-title":"Trends Neurosci"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.it.2010.05.005","article-title":"FADD: a regulator of life and death","volume":"31","author":"L Tourneur","year":"2010","journal-title":"Trends Immunol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0070952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T02:06:42Z","timestamp":1715825202000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0070952"}},"subtitle":[],"editor":[{"given":"Cheng-Xin","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,5]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0070952","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,5]]}}}